British American Tobacco Signals Cautious Growth Momentum
British American Tobacco ((BTI)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Management struck a cautiously upbeat tone, emphasizing that British American Tobacco is delivering at the top end of guidance while accelerating its shift into smokeless products. Strong cash generation, rising dividends, and buybacks underpinned confidence, even as executives conceded persistent pressure from vapour declines, illicit trade, and weakness in APMEA.
Smokeless Consumer Growth
BAT added 4.7 million smokeless consumers in 2025, taking the total to 34.1 million and marking its strongest acceleration so far. Management framed this as proof that its pivot beyond cigarettes is gaining traction, with Modern Oral the main engine positioning the group for further gains into 2026.
Group Results at Top End of Guidance
Group performance landed at the top end of constant-currency guidance, with revenue up 2.1% and adjusted profit rising 3.4%. Adjusted profit from operations increased 2.3% and adjusted diluted EPS grew 3.4%, underscoring solid execution despite significant regulatory and currency headwinds.
Modern Oral Outperformance
New Categories revenue advanced 7%, led by a standout 48% surge in Modern Oral, where BAT claims global leadership in key markets. In the U.S., Velo Plus grew more than 300% since launch and reached positive category contribution within its first year, supporting Velo’s global share leadership in Modern Oral.
U.S. Combustibles and Overall U.S. Strength
The U.S. remained a profit engine, with overall revenue up 5.5% and adjusted profit increasing 5.9%. Combustibles revenue grew 4.6% as value share rose by 30 basis points, while New Category revenue in the U.S. climbed nearly 20% and Vuse returned to revenue growth in the second half.
New Category Profitability and Contribution
Profitability in New Categories improved sharply as gross profit rose by more than GBP 200 million. Category contribution reached GBP 442 million and has improved by about GBP 1.4 billion since 2021, reinforcing management’s case that reduced-risk products are becoming a meaningful earnings driver.
Operational Efficiency and Productivity Savings
BAT highlighted a strong efficiency push, having delivered GBP 1.2 billion in productivity savings since 2023 and targeting a further GBP 2 billion by 2030. The Fit2Win program is expected to add GBP 600 million of annualized incremental savings by 2028, with GBP 500 million already targeted by 2027.
Strong Cash Generation and Shareholder Returns
Robust cash generation is translating into richer shareholder returns, with a 2% dividend increase and a larger 2026 buyback of GBP 1.3 billion. The company has reduced leverage to 2.55x adjusted net debt to EBITDA and aims to deliver more than GBP 50 billion of free cash flow by 2030 while moving toward a 2.0–2.5x leverage range.
Regional AME Outperformance
The AME region was a bright spot, delivering revenue growth above 3%, with Combustibles up more than 2% and New Category revenue rising 4.3%. Modern Oral grew 17% and, together with operating leverage and cost efficiencies, helped lift AME adjusted operating profit by nearly 10%.
Vapour Category Weakness and Illicit Market Pressure
Vapour weighed on results, with revenue declining nearly 9% for the year and mid-teens in the first half, largely due to illicit competition in the U.S. and Canada. AME vapour revenue fell more than 11%, and Vuse finished the year down about 3.4% despite some recovery signs later in the year.
APMEA Revenue and Profit Decline
In contrast to AME, the APMEA region posted a 7.2% revenue decline, with Combustibles down 8.3% and New Categories down 7.6%. Adjusted profit dropped 17.9%, as regulatory and fiscal pressure in markets like Bangladesh and Australia hit volumes, mix, and profitability.
Regulatory and Fiscal Headwinds in Key Markets
Fiscal and regulatory measures in Bangladesh and Australia shaved roughly 1% off group revenue and around 2% off adjusted profit from operations. Australia’s combustible market is now heavily disrupted, with very high illicit penetration eroding the legal market and complicating BAT’s pricing and volume strategy.
Heated Products Competitive Pressure
Heated tobacco products faced tougher competition, particularly in value-for-money segments impacting the glo HYPER franchise. To regain momentum, BAT is rolling out glo Hilo and next-generation glo HYPER devices, signaling ongoing investment to defend share in this strategically important category.
Transactional FX and One-off Items
Currency movements were a drag, with transactional FX reducing adjusted profit by around 1%, most notably in Turkey, Japan, and Nigeria. Reported results were also shaped by adjusting items, including substantial amortization of U.S. trademarks, a net credit linked to Canada, and a gain on partial monetization of the ITC stake.
Fit2Win Implementation Costs
The broader Fit2Win rollout will come with near-term costs of about GBP 600 million over the next two years, most of which will be treated as adjusting items. Around GBP 100 million of this is non-cash, and the company expects the bulk of the spending to fall in 2026 and 2027 as savings ramp up.
Conservative 2026 Guidance and Phasing Risks
Management warned that 2026 is likely to track at the lower end of its midterm algorithm of 3–5% revenue growth, with profit skewed to the second half. The cautious stance reflects lingering APMEA instability, uncertain timing of vapour enforcement, and the phasing of investment in New Categories alongside Fit2Win execution.
Forward-looking Guidance and Strategic Priorities
BAT targets a return to its midterm ranges of 3–5% revenue growth, 4–6% adjusted operating profit growth, and 5–8% EPS growth, with 2026 at the low end but supported by low double-digit New Category revenue growth led by Velo. Long-term priorities center on more than GBP 50 billion of free cash flow to 2030, a progressive dividend, a GBP 1.3 billion annual buyback, and ongoing deleveraging as productivity and Fit2Win savings accumulate.
The earnings call painted a picture of a business in transition but with growing financial firepower to fund change and reward shareholders. Strong U.S. and Modern Oral trends, rising New Category profitability, and aggressive cost savings are counter-balancing regulatory shocks and vapour and APMEA headwinds, leaving BAT positioned as a cash-rich but still cautiously guided income stock for investors to watch.
